Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 1, 2007, Pages 52-64

  Maddineni, Jyothi ^a   Hoppensteadt, Debra A ^a   Cornelli, Umberto ^b   Manoni, Marco ^c   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b Corcon ^*  (Italy)

^c Inalco   (Italy)

Author keywords

Bioheparin fractions; Bioheparins; K5 derivatives; Low molecular weight heparins (LMWHs); Sulfaminoheparosans (SAHs); Unfractionated heparin (UFH)

Indexed keywords

ANTICOAGULANT AGENT; BACTERIAL POLYSACCHARIDE; BLOOD CLOTTING FACTOR 10A; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; POLYMER; PROTAMINE SULFATE; PROTHROMBIN A; SULFAMINOHEPAROSAN DERIVATIVE; TINZAPARIN;

ANTICOAGULATION; ARTICLE; ASSAY; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEPTEST; HUMAN; IN VIVO STUDY; MOLECULAR WEIGHT; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN INDUCED CLOTTING TIME; PROTHROMBIN TIME; VALIDATION PROCESS;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN ANTAGONISTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR WEIGHT; POLYSACCHARIDES, BACTERIAL; PROTAMINES; TITRIMETRY;

EID: 33845452435     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606296403     Document Type: Article

References (24)

1. Stevens RL, et al. Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc Natl Acad Sci USA 1988 ; 85: 2284-2284.
2. Langer R, Linhardt RJ, Cooney CL, et al. An enzymatic system for removing heparin in extracorporeal therapy. Science 1982 ; 217: 261-261.
3. Freedman MD. Pharmacodynamics, clinical indications and adverse effects of heparin. J Clin Pharmacol 1992 ; 32: 584-584.
4. Linhardt RJ, et al. Heparin oligosaccharides: New analogues development and applications. Marcel Dekker Inc., NY ; 1997: 277-277.
5. Susan BP, Promes, Tammei Quest, et al. Low molecular weight heparins in emergency practice: Guidelines and protocols for thrombosis management - Acute ischemic syndromes and deep venous thrombosis. Emerg Med Rep www.ahcpub.com.
6. Linhardt RJ. Heparin: An important drug enters its seventh decade. Chem Indust 1991 ; 2: 45-45.
7. Nader HB, Lopes CC, Rocha HA, et al. Heparins and heparinoids: Occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr Pharm Des 2004 ; 10 (9). 951-951.
8. Coyne E. From heparin to heparin fraction and derivatives. Semin Thromb Hemost 1985 ; 11: 10-10.
9. Volpi N. Occurrence and structural characterization of heparin from molluscs. ISJ 2005 ; 2: 6-6.
10. Coyne E, Messmore H, Walenga JM, et al. Fish skin glycosaminoglycans: a source for highly sulfated chondroitin sulfates. Thromb Haemost 1995 ; 73 (6). 1728-1728.
11. Casu B, Grazioli G, Razi N, et al. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res 1994 ; 263: 271-271.
12. Naggi A, Torri G, Casu B, et al. Toward a bitechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysachharide. Semin Thromb Hemost 2001 ; 27 (5). 437-437.
13. Griffiths G, Barrett B, Cook N, et al. Biosynthesis of the Escherichia coli K5 polysaccharide. Biochem Soc Trans 1999 ; 27 (4). 507-507.
14. Kusche M, Hannenson HH, Lindahl U, et al. Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzymic polymer-modification reactions. Biochem J 1991 ; 275 (pt 1): 151-151.
15. Maddineni J, Ma Q, Hoppensteadt D, et al. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan. Clin Appl Thromb Hemost 2004 ; 10 (1). 27-27.
16. Holst J, Lindblad B, Bergqvist D, et al. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man. Thromb Res 1997 ; 86 (4). 343-343.
17. Teoh KH, Young E, Blackall MH, et al. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 2004 ; 128 (2). 211-211.
18. Liang JF, Zhen L, Chang LC, et al. A less toxic heparin antagonist - low molecular weight protamine. Biochemistry (Moscow) 2003 ; 68: 116-116.
19. Li-Chien Chang, Shirley W, Thomas WW, et al. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS Pharmsci 2001 ; 3 ( 2 ):article 19.
20. Svenarud P, Ovrum E. Clinical effects of different protamine doses after cardiopulmonary bypass. Asian Cardiovasc Thorac Ann 2002.
21. Huang TH, Ordu Y, Demple G, et al. Binding of heparins to protamine. Thromb Hemost 1989 ; 62 (1). 514-514.
22. Racanelli A. Biochemical and pharmacological studies on the interaction of protamine with heparins. PhD dissertation, 1990.
23. Van Ryn-McKenna J, et al. Neutralization of enoxaparininduced bleeding by protamine sulfate. Thromb Haemost 1990 ; 63 (2). 271-271.
24. Maddineni J. Molecular weight dependence on pharmacological actions of sulfaminoheparosans of bacterial origin. Unpublished master's thesis. Loyola University, Maywood, IL.